Fumaric Acid

Fumaric Acid

SCHEMBL7007957

O=C(O)/C=C/C(=O)O.c1ccc(N2CCCC23CCN(C2CCCCCCCCC2)CC3)cc1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol

The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.46
OPRD1 P41143 2/20 0.46
OPRK1 P41145 2/20 0.46
OPRL1 P41146 2/20 0.46
HRH3 Q9Y5N1 3/20 0.45
SLC18A3 Q16572 1/20 0.43
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 3/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL7007959 1.00 OPRM1 (0.46) OPRM1OPRD1OPRK1OPRL1HRH3
Fumaric Acid SCHEMBL7878795 0.95 OPRM1 (0.47) OPRM1OPRD1OPRK1OPRL1HRH3
Fumaric Acid SCHEMBL7883803 0.95 OPRM1 (0.47) OPRM1OPRD1OPRK1OPRL1HRH3
Fumaric Acid SCHEMBL7883810 0.95 OPRM1 (0.47) OPRM1OPRD1OPRK1OPRL1HRH3
Fumaric Acid SCHEMBL7886495 0.95 OPRM1 (0.47) OPRM1OPRD1OPRK1OPRL1HRH3
Fumaric Acid SCHEMBL7886498 0.95 OPRM1 (0.47) OPRM1OPRD1OPRK1OPRL1HRH3
Fumaric Acid SCHEMBL7883826 0.95 OPRM1 (0.47) OPRM1OPRD1OPRK1OPRL1HRH3
Fumaric Acid SCHEMBL7883822 0.95 OPRM1 (0.47) OPRM1OPRD1OPRK1OPRL1HRH3
Fumaric Acid SCHEMBL7878800 0.95 OPRM1 (0.47) OPRM1OPRD1OPRK1OPRL1HRH3
Fumaric Acid SCHEMBL7014518 0.90 OPRL1 (0.44) OPRM1OPRD1OPRK1OPRL1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642247-B2 Treting anxiety, stress, depression, trauma, Alzheimer's mediated memory loss, epilepsy, arterial blood pressure disorders, obesity, acute pain, chronic pain, Na+ excretion, control of water balance, and symptoms associated with drug HOFFMAN-LA ROCHE INC. 2003-11-04 US disclosed
US-20030176701-A1 DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-18 US disclosed
EP-0963985-B1 Di-or triaza-spiro(4,5)decane derivatives HOFFMANN LA ROCHE (CH) 2003-03-12 EP disclosed
EP-0963985-A2 Di-or triaza-spiro(4,5)decane derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176701-A1 DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES NPY4R, NPY1R, OXER1 OPRM1 152/4885OPRD1 103/4885OPRK1 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.